• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Commissioner Says Agency Wants to Develop Master Protocol Trials to Test Multiple COVID-19 Drug and Vaccine Candidates at Once

FDA Commissioner Says Agency Wants to Develop Master Protocol Trials to Test Multiple COVID-19 Drug and Vaccine Candidates at Once

April 20, 2020

To get COVID-19 vaccine and therapeutics candidates through the pipeline faster, FDA Commissioner Stephen Hahn said yesterday that the agency is interested in developing master protocols, possibly in conjunction with regulatory agencies in other countries.

In contrast to traditional trial designs, where a single drug is tested in a single disease population in one clinical trial, master protocols use a single infrastructure, trial design and protocol to simultaneously evaluate multiple drugs and/or disease populations in multiple substudies, allowing for efficient and accelerated drug development. The drug candidates are each compared to the control group but not to one another.

“It’s a very efficient way of looking at multiple different therapeutics, vaccines,” said Hahn in a public presentation.

If FDA gets behind a master protocol trial to focus on COVID-19 candidates, it won’t be the first time the agency used that trial design to address a pandemic. During the 2015 Ebola outbreak in Africa, the FDA and the National Institutes for Allergy and Infectious Disease employed a master protocol to test multiple therapeutic candidates. The Ebola epidemic faded before the trial showed robust results, but the design held up. The FDA said then that the master protocol concept “successfully illustrated the feasibility and desirability of innovative trial designs to meet the demands of a public health crises.”

In late March, the World Health Organization proposed a master protocol for companies and institutions that aim to test therapeutics against COVID-19.

FDA announced the availability of a draft guidance for master protocols — also called basket trials, umbrella trials and platform trials — in 2018 for sponsors working on cancer drugs.

Examples of trials now using master protocols include: the Lung-MAP trial, which is testing several different treatments that target genetic changes found in non-small cell lung cancer; the NCI-MATCH trial, a phase 2 study endeavoring to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer regardless of their cancer type; and the Pediatric MATCH trial, a phase 2 trial that aims to investigate more than eight study drugs, each targeting a defined set of gene mutations, in order to match patients with therapies aimed at the molecular abnormalities in his or her tumor.

COVID-19
    • Related Directories

      Olumiant (baricitinib)

      Veklury (remdesivir)

      Comirnaty (COVID-19 Vaccine, mRNA)

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing